[Performance of high-risk HPV typing test in early diagnosis of cervical cancer].

Objective: To evaluate the performance of High-risk HPV typing detection in cervical cancer screening. Methods: A total of 3 231 women were recruited as the subjects of cervical cancer screening from Jiyuan city of Henan provinces from June to July 2017. All women underwent HPV DNA test. The women with cytological examination ≥ASCUS or cytological examination negative and HPV 16/18 positive underwent colposcopy biopsy and pathological examination. Pathological diagnosis was used as the gold standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value(NPV) as well as corresponding 95% confidence interval ( CI ) of HR-HPV and HPV 16/18 were calculated. Results: The mean age of 3 231 subjects selected in this study was 46.84±10.00 (21-64) years old. 524 subjects had the positive results of HR-HPV, including 91 of HPV16 and 15 of HPV18. Pathological test result CIN2+ was the gold standard. The sensitivity and specificity of HR-HPV for cervical precancer lesions screening were 93.75 (95 %CI : 79.85-98.27) and 84.56% (95 %CI : 83.26-85.77), respectively. To compared with HR-HPV, HPV16/18 had low sensitivity (65.63%, 95 %CI : 48.31-79.59)and higher specificity (97.44%, 95 %CI : 96.83-97.93). After age stratification by age 30 and 45, the sensitivity of HPV 16/18 was same with HR-HPV (100%, 95 %CI : 34.24-100.00), the specificity of HPV 16/18 was higher than HR-HPV (98.71%, 95 %CI : 96.27-99.56 vs 84.48%, 95 %CI : 79.27-88.58) in < 30 age group.The sensitivity of HR-HPVin 30-45 and ≥45 age group were higher than HPV16/18 (85.71%, 95 %CI : 48.69-97.43 vs 71.43%, 95 %CI : 35.89-91.78, 95.65%, 95 %CI : 79.01-99.23 vs 60.87%, 95 %CI : 40.79-77.84), but the specificity werelower than HPV16/18 (86.89%, 95 %CI : 84.58-88.90 vs 98.51%, 95 %CI : 97.51-99.11、83.49%, 95 %CI : 81.81-85.04 vs 96.80%, 95 %CI : 95.94-97.48). Conclusions: HR-HPV detection has relatively high sensitivity and specificity in cervical cancer screening. For > 30 years old women, HR-HPV is more recommended in cervical cancer screening. Therefore, HR-HPV detection is an effective method for cervical cancer screening.